CD28 and diffuse large B-cell lymphoma: They are Tisagenlecleucel (co-stimulatory domain 4-1BB/CD3ζ), approved in 2017 for B-ALL and in 2018 for DLBCL; and axicabtagene ciloleucel (co-stimulatory domain CD28/ CD3ζ), approved in 2017 for DLBCL.